{"organizations": [], "uuid": "f3499d10ec78c120b057f404d0e9be6a85bef103", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/health-amgen/amgen-loses-case-over-fda-denial-of-sensipar-pediatric-exclusivity-idUSL2N1QA1WK", "country": "US", "domain_rank": 408, "title": "Amgen loses case over FDA denial of Sensipar pediatric exclusivity", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T06:55:00.000+02:00", "replies_count": 0, "uuid": "f3499d10ec78c120b057f404d0e9be6a85bef103"}, "author": "Nate Raymond", "url": "https://www.reuters.com/article/health-amgen/amgen-loses-case-over-fda-denial-of-sensipar-pediatric-exclusivity-idUSL2N1QA1WK", "ord_in_thread": 0, "title": "Amgen loses case over FDA denial of Sensipar pediatric exclusivity", "locations": [], "entities": {"persons": [{"name": "randolph moss", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "d.c.", "sentiment": "none"}, {"name": "washington", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "amgen", "sentiment": "negative"}, {"name": "johnson & johnson", "sentiment": "none"}, {"name": "amgen inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "A federal judge has ruled that the U.S. Food and Drug Administration acted reasonably when it declined last year to grant Amgen Inc a six-month period of marketing exclusivity for pediatric uses of its kidney drug Sensipar.\nU.S. District Judge Randolph Moss in Washington, D.C. on Saturday rejected Amgen’s contention that the FDA’s actions were inconsistent with its earlier decision to grant Johnson & Johnson pediatric exclusivity for an oral contractive.\nTo read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2sFF6Or\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2sFF6Or"], "published": "2018-02-21T06:55:00.000+02:00", "crawled": "2018-02-21T21:06:29.008+02:00", "highlightTitle": ""}